Using State-of-the-Art, Patient-Centric Neuromodulation Therapy, XII Medical is Revolutionizing the Treatment of Obstructive Sleep Apnea

Nearly 1 billion people worldwide suffer from obstructive sleep apnea (OSA), a disorder in which the muscles in the throat temporarily relax, causing blockage of the airway during sleep. Despite ongoing advancements in OSA therapies, existing treatment options remain overly burdensome to both patients and physicians, leaving a significant number of people suffering from OSA untreated, under-treated and at risk of dangerous health complications.?

XII Medical is a clinical-stage medical technology company developing a state-of-the-art, patient-centric neuromodulation therapy that enhances quality of life for people suffering from OSA. Today, the company announced its $45 million Series B, which will be used to further advance product and clinical development. We’re thrilled to participate in this round, alongside Omega Funds, Cleveland Clinic, Ajax Health, Broadview Ventures, Aperture Venture Partners and JobsOhio Growth Equity Fund.

At Intuitive Ventures, we’re committed to supporting companies that are improving patient outcomes via minimally invasive care. We’re proud to back XII Medical as it works to make best-in-class OSA therapy accessible to anyone who needs it. The raise will allow the company to expand its team and collaborate with additional partners to further develop its pioneering technology and clinical research.?

Congratulations to the entire XII Medical team!